Eight $250,000 prizes will be awarded for key milestones in FSHD treatments and $8 million will be given for showing clinical ...

Facioscapulohumeral muscular dystrophy (FSHD) is the third most common form of inherited muscle disease following Duchenne and myotonic dystrophy. FSHD is initially characterized by an asymmetric ...

FSHD exacts a toll on columnist Robin Stemple when he is out and about. He calls these symptom flares "FSHD hangovers." ...

a venture philanthropy organization dedicated to catalyzing innovation and overcoming barriers to accelerate new therapies for facioscapulohumeral muscular dystrophy (FSHD), is calling on innovators ...

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

The three-horse race to treat a devastating form of muscular dystrophy is now down to two. One of the key players, Avidity ...

Shares of Sarepta Therapeutics SRPT rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global ...

The first is ARO-DUX4, which is being developed as a potential treatment for patients with facioscapulohumeral muscular dystrophy (FSHD), while ARO-DM1 is being developed to treat myotonic ...